OverviewSuggest Edit

ViaCyte is a regenerative medicine company focused on developing a transformative cell replacement therapy to free people with insulin-requiring diabetes from painful and frequent insulin injections, strict diet regimens, constant blood sugar monitoring, and serious chronic health conditions associated with the disease.

ViaCyte's innovative product is based on the differentiation of stem cells into pancreatic beta cell precursors with subcutaneous implantation in a retrievable and immune-protective encapsulation medical device. Once implanted, the precursor cells mature into endocrine cells that secrete insulin and other hormones in a regulated manner to control blood glucose levels.

... Show more
TypePrivate
Founded1999
HQSan Diego, US
Websiteviacyte.com
Employee Ratings3.6

Latest Updates

Employees (est.) (Feb 2019)64(+4%)

ViaCyte Office Locations

ViaCyte has an office in San Diego
San Diego, US (HQ)
3550 General Atomics Ct
Show all (1)
Report incorrect company information

ViaCyte Financials and Metrics

Summary Metrics

Founding Date

1999

ViaCyte total Funding

$174.9 m

ViaCyte latest funding size

$80 m

Time since last funding

3 months ago

ViaCyte investors

ViaCyte's latest funding round in November 2018 was reported to be $80 m. In total, ViaCyte has raised $174.9 m
View all funding rounds
Report incorrect company information

ViaCyte Online and Social Media Presence

Embed Graph
Report incorrect company information

ViaCyte News and Updates

Center for Beta Cell Therapy in Diabetes and ViaCyte Announce Start of European Clinical Trial of Human Stem Cell-derived Implants in Type 1 Diabetes Patients

BRUSSELS and SAN DIEGO, Jan. 21, 2019 /PRNewswire/ -- The Center for Beta Cell Therapy in Diabetes, coordinator of an international consortium in translational medicine in diabetes, and ViaCyte, Inc., a privately held regenerative medicine company, today announced that a human stem...

ViaCyte Secures $80 Million Financing to Advance Functional Cures for Insulin-Requiring Diabetes

SAN DIEGO, Nov. 29, 2018 /PRNewswire/ -- ViaCyte, Inc., a privately-held clinical stage regenerative medicine company, today announced an $80 million Series D financing led by Bain Capital Life Sciences and joined by TPG and RA Capital Management, as well as existing investor, Sanderling...

Two-year Data from ViaCyte's STEP ONE Clinical Trial Presented at ADA 2018

SAN DIEGO, June 23, 2018 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company, today announced two-year data from Cohort 1 of the ongoing Safety, Tolerability, and Efficacy of VC-01™ (PEC-Encap™) Product Candidate in Type One Diabetes (STEP ONE) clinical trial....
Report incorrect company information

ViaCyte Blogs

IPITA and ADA Conference Recap: Preliminary Data from Two-Year STEP ONE Trial and Encaptra® Modification

ViaCyte recently presented preliminary two-year data from the STEP ONE (Safety, Tolerability, and Efficacy of VC-01 Combination Product in Type One Diabetes) as well as early results from preclinical studies on a modified Encaptra® Cell Delivery System.  These data were presented at two conferences:…

ViaCyte Company Life and Culture

Report incorrect company information

ViaCyte Frequently Asked Questions

  • When was ViaCyte founded?

    ViaCyte was founded in 1999.

  • How many employees does ViaCyte have?

    ViaCyte has 64 employees.

  • Who are ViaCyte competitors?

    Competitors of ViaCyte include MannKind Corporation, Orgenesis and Emisphere Technologies.

  • Where is ViaCyte headquarters?

    ViaCyte headquarters is located at 3550 General Atomics Ct, San Diego.

  • Where are ViaCyte offices?

    ViaCyte has an office in San Diego.

  • How many offices does ViaCyte have?

    ViaCyte has 1 office.